Skip to main content
SpringerLink
Log in

Staphylococcal Infection

  • Chapter
  • First Online:
The Infectious Diseases Consult Handbook

  • 290 Accesses

Abstract

“We’ve got a really sick patient who just started growing four out of four bottles with gram-positive cocci in clusters—can you help?” You will hear a variation of this line over and over again throughout ID fellowship. Staphylococcus aureus, especially the infamous methicillin-resistant S. aureus (MRSA), remains a common and often challenging clinical scenario where ID consultants are called for their expertise. Methicillin-susceptible S. aureus (MSSA) is no slouch either. In general, S. aureus has continued to evolve and pick up new tricks, such as increasing exotoxins and resistance mechanisms. Changes in clinical populations, such as increasing rates of injection drug use, have increased the prevalence of staphylococcal disease.

Given its disproportionally large role in the life of a first-year ID fellow, the staphylococci have earned an entire chapter in this text. We will primarily discuss bacteremia as other specific sites of focus such as staphylococcal endocarditis and osteomyelitis will be reviewed in their respective anatomic chapters. If time on the ID service teaches one lesson, it is to never underestimate the resourcefulness of S. aureus!

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mylotte JM, Tayara A. Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort. Clin Infect Dis. 2000;31:1170. https://doi.org/10.1086/317421.

    Article  CAS  PubMed  Google Scholar 

  2. Vogel M, Schmitz RPH, Hagel S, Pletz MW, Gagelmann N, Scherag A, Schlattmann P, Brunkhorst FM. Infectious disease consultation for Staphylococcus aureus bacteremia - a systematic review and meta-analysis. J Infect. 2016;72:19. https://doi.org/10.1016/j.jinf.2015.09.037.

    Article  PubMed  Google Scholar 

  3. Forsblom E, Ruotsalainen E, Ollgren J, Järvinen A. Telephone consultation cannot replace bedside infectious disease consultation in the management of staphylococcus aureus bacteremia. Clin Infect Dis. 2013;56:527. https://doi.org/10.1093/cid/cis889.

    Article  CAS  PubMed  Google Scholar 

  4. Djelic L, Andany N, Craig J, Daneman N, Simor A, Leis JA. Automatic notification and infectious diseases consultation for patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis. 2018;91:282. https://doi.org/10.1016/j.diagmicrobio.2018.03.001.

    Article  PubMed  Google Scholar 

  5. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:285. https://doi.org/10.1093/cid/ciq146.

    Article  PubMed  Google Scholar 

  6. Berrevoets MAH, Kouijzer IJE, Aarntzen EHJG, Janssen MJR, De Geus-Oei LF, Wertheim HFL, Kullberg BJ, Oever JT, Oyen WJG, Bleeker-Rovers CP. 18F-FDG PET/CT optimizes treatment in staphylococcus aureus bacteremia and is associated with reduced mortality. J Nucl Med. 2017;58:1504. https://doi.org/10.2967/jnumed.117.191981.

    Article  CAS  PubMed  Google Scholar 

  7. Berrevoets MAH, Kouijzer IJE, Slieker K, Aarntzen EHJG, Kullberg BJ, Oever JT, Bleeker-Rovers CP. 18F-FDG PET/CT-guided treatment duration in patients with high-risk staphylococcus aureus bacteremia: a proof of principle. J Nucl Med. 2019;60:998. https://doi.org/10.2967/jnumed.118.221929.

    Article  CAS  PubMed  Google Scholar 

  8. Khatib R, Johnson LB, Fakih MG, Riederer K, Khosrovaneh A, Tabriz MS, Sharma M, Saeed S. Persistence in staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis. 2006;38:7. https://doi.org/10.1080/00365540500372846.

    Article  PubMed  Google Scholar 

  9. Minejima E, Mai N, Bui N, Mert M, Mack WJ, She RC, Nieberg P, Spellberg B, Wong-Beringer A. Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes. Clin Infect Dis. 2020;70:566. https://doi.org/10.1093/cid/ciz257.

    Article  PubMed  Google Scholar 

  10. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653. https://doi.org/10.1056/nejmoa053783.

    Article  CAS  PubMed  Google Scholar 

  11. Kuehl R, Morata L, Boeing C, Subirana I, Seifert H, Rieg S, Kern WV, Kim HB, Kim ES, Liao CH, Tilley R, Lopez-Cortés LE, Llewelyn MJ, Fowler VG, Thwaites G, Cisneros JM, Scarborough M, Nsutebu E, Gurgui Ferrer M, Pérez JL, Barlow G, Hopkins S, Ternavasio-de la Vega HG, Török ME, Wilson P, Kaasch AJ, Soriano A, Kern WV, Llewelyn MJ, Fowler VG, Pérez JL, Török E, Kaasch AJ, Bernasch C, Jung N, Lamarca Soria K, Rivera Martínez MA, Prim N, Martínez JA, Marcos M, Baño JR, De Cueto M, Sung KH, Kim CJ, Kang CK, Park JI, Morris-Jones S, Kamfose M, Young B, Gott H, Gouliouris T, Bedford L, Price J. Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study. Lancet Infect Dis. 2020;20:1409. https://doi.org/10.1016/S1473-3099(20)30447-3.

    Article  CAS  PubMed  Google Scholar 

  12. Foster TJ. Can β-lactam antibiotics be resurrected to combat MRSA? Trends Microbiol. 2019;27:26. https://doi.org/10.1016/j.tim.2018.06.005.

    Article  CAS  PubMed  Google Scholar 

  13. Davis JS, Sud A, O’Sullivan M, Robinson JO, Ferguson PE, Foo H, Van Hal SJ, Ralph AP, Howden BP, Binks PM, Kirby A, Tong S, Binks P, Majumdar S, Ralph A, Baird R, Gordon C, Jeremiah C, Leung G, Brischetto A, Crowe A, Dakh F, Whykes K, Kirkwood M, Menon M, Somerville L, Subedi S, Owen S, Liu E, Zhou F, Robinson O, Coombs G, Ferguson P, Pollet S, Van Hal S, Davis R. Combination of vancomycin and β-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis. 2016;62:173. https://doi.org/10.1093/cid/civ808.

    Article  CAS  PubMed  Google Scholar 

  14. Tong SYC, Lye DC, Yahav D, Sud A, Robinson JO, Nelson J, Archuleta S, Roberts MA, Cass A, Paterson DL, Foo H, Paul M, Guy SD, Tramontana AR, Walls GB, McBride S, Bak N, Ghosh N, Rogers BA, Ralph AP, Davies J, Ferguson PE, Dotel R, McKew GL, Gray TJ, Holmes NE, Smith S, Warner MS, Kalimuddin S, Young BE, Runnegar N, Andresen DN, Anagnostou NA, Johnson SA, Chatfield MD, Cheng AC, Fowler VG, Howden BP, Meagher N, Price DJ, Van Hal SJ, O’Sullivan MVN, Davis JS. Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA. 2020;323:527. https://doi.org/10.1001/jama.2020.0103.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Pujol M, Miró JM, Shaw E, Aguado JM, San-Juan R, Puig-Asensio M, Pigrau C, Calbo E, Montejo M, Rodriguez-Álvarez R, Garcia-Pais MJ, Pintado V, Escudero-Sánchez R, Lopez-Contreras J, Morata L, Montero M, Andrés M, Pasquau J, Arenas MDM, Padilla B, Murillas J, Jover-Sáenz A, López-Cortes LE, García-Pardo G, Gasch O, Videla S, Hereu P, Tebé C, Pallarès N, Sanllorente M, Domínguez MÁ, Càmara J, Ferrer A, Padullés A, Cuervo G, Carratalà J. Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial. Clin Infect Dis. 2021;72:1517. https://doi.org/10.1093/cid/ciaa1081.

    Article  CAS  PubMed  Google Scholar 

  16. Cheng MP, Lawandi A, Butler-Laporte G, De l’Étoile-Morel S, Paquette K, Lee TC. Adjunctive daptomycin in the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a randomized, controlled trial. Clin Infect Dis. 2021;72:e196. https://doi.org/10.1093/cid/ciaa1000.

    Article  CAS  PubMed  Google Scholar 

  17. Geriak M, Haddad F, Rizvi K, Rose W, Kullar R, LaPlante K, Yu M, Vasina L, Ouellette K, Zervos M, Nizet V, Sakoulas G. Clinical data on Daptomycin plus Ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2019;63 https://doi.org/10.1128/AAC.02483-18.

  18. Nichols CN, Wardlow LC, Coe KE, Sobhanie MME. Clinical outcomes with definitive treatment of methicillin-resistant Staphylococcus aureus bacteremia with retained daptomycin and Ceftaroline combination therapy vs de-escalation to monotherapy with vancomycin, daptomycin, or ceftaroline. Open Forum Infect Dis. 2021;8 https://doi.org/10.1093/ofid/ofab327.

  19. McDanel JS, Perencevich EN, Diekema DJ, Herwaldt LA, Smith TC, Chrischilles EA, Dawson JD, Jiang L, Goto M, Schweizer ML. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. Clin Infect Dis. 2015;61:361. https://doi.org/10.1093/cid/civ308.

    Article  CAS  PubMed  Google Scholar 

  20. Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh MD, Choe KW. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2008;52:192. https://doi.org/10.1128/AAC.00700-07.

    Article  CAS  PubMed  Google Scholar 

  21. Chang FY, Peacock JE, Musher DM, Triplett P, MacDonald BB, Mylotte JM, O’Donnell A, Wagener MM, Yu VL. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine. 2003;82:333. https://doi.org/10.1097/01.md.0000091184.93122.09.

    Article  CAS  PubMed  Google Scholar 

  22. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2004;48:4665. https://doi.org/10.1128/AAC.48.12.4665-4672.2004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Le J, Dam Q, Schweizer M, Thienphrapa W, Nizet V, Sakoulas G. Effects of vancomycin versus nafcillin in enhancing killing of methicillin-susceptible Staphylococcus aureus causing bacteremia by human cathelicidin LL-37. Eur J Clin Microbiol Infect Dis. 2016;35:1441. https://doi.org/10.1007/s10096-016-2682-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Flynt LK, Kenney RM, Zervos MJ, Davis SL. The safety and economic impact of cefazolin versus Nafcillin for the treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections. Infect Dis Ther. 2017;6:225. https://doi.org/10.1007/s40121-017-0148-z.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Frame PT, Watanakunakorn C, McLaurin RL, Khodadad G. Penetration of nafcillin, methicillin, and cefazolin into human brain tissue. Neurosurgery. 1983;12:142. https://doi.org/10.1227/00006123-198302000-00002.

    Article  CAS  PubMed  Google Scholar 

  26. Le Turnier P, Gregoire M, Deslandes G, Lakhal K, Deschanvres C, Lecomte R, Talarmin JP, Dubée V, Bellouard R, Boutoille D, Leroy AG, Gaborit BJ, Raffi F, Boutoille D, Biron C, Lefebvre M, Gaborit BJ, Le Turnier P, Deschanvres C, Lecomte R, Chauveau M, Asseray N, Gregoire M, Bellouard R, Deslandes G, Dailly E, Leroy AG, Corvec S, Bémer P, Caillon J, Guillouzouic A, Lakhal K, Cinotti R, Canet E, Bretonniere C, Guimard T, Brochard J, Talarmin JP, Katchatourian L. Should we reconsider cefazolin for treating staphylococcal meningitis? A retrospective analysis of cefazolin and cloxacillin cerebrospinal fluid levels in patients treated for staphylococcal meningitis. Clin Microbiol Infect. 2020;26:1415.e1. https://doi.org/10.1016/j.cmi.2020.04.046.

    Article  CAS  PubMed  Google Scholar 

  27. Luria SE. A test for penicillin sensitivity and resistance in staphylococcus. Proc Soc Exp Biol Med. 1946;61:46. https://doi.org/10.3181/00379727-61-15222.

    Article  CAS  PubMed  Google Scholar 

  28. Zygmunt DJ, Stratton CW, Kernodle DS. Characterization of four β-lactamases produced by Staphylococcus aureus. Antimicrob Agents Chemother. 1992;36:440. https://doi.org/10.1128/AAC.36.2.440.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Miller WR, Seas C, Carvajal LP, Diaz L, Echeverri AM, Ferro C, Rios R, Porras P, Luna C, Gotuzzo E, Munita JM, Nannini E, Carcamo C, Reyes J, Arias CA. The cefazolin inoculum effect is associated with increased mortality in methicillin-susceptible staphylococcus aureus bacteremia. Open Forum Infect Dis. 2018;5 https://doi.org/10.1093/ofid/ofy123.

  30. Weis S, Kesselmeier M, Davis JS, Morris AM, Lee S, Scherag A, Hagel S, Pletz MW. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2019;25:818. https://doi.org/10.1016/j.cmi.2019.03.010.

    Article  CAS  PubMed  Google Scholar 

  31. Timbrook TT, McKay L, Sutton JD, Spivak ES. Disproportionality analysis of safety with nafcillin and oxacillin with the FDA adverse event reporting system (FAERS). Antimicrob Agents Chemother. 2020;64 https://doi.org/10.1128/AAC.01818-19.

  32. Viehman JA, Oleksiuk LM, Sheridan KR, Byers KE, He P, Falcione BA, Shields RK. Adverse events lead to drug discontinuation more commonly among patients who receive nafcillin than among those who receive oxacillin. Antimicrob Agents Chemother. 2016;60:3090. https://doi.org/10.1128/AAC.03122-15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Maraqa NF, Gomez MM, Rathore MH, Alvarez AM. Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. Clin Infect Dis. 2002;34:50. https://doi.org/10.1086/338047.

    Article  CAS  PubMed  Google Scholar 

  34. Hamad Y, Connor L, Bailey TC, George IA. Outcomes of outpatient parenteral antimicrobial therapy with ceftriaxone for methicillin-susceptible staphylococcus aureus bloodstream infections-a single-center observational study. Open Forum Infect Dis. 2020;7 https://doi.org/10.1093/ofid/ofaa341.

  35. Kamfose MM, Muriithi FG, Knight T, Lasserson D, Hayward G. Intravenous ceftriaxone versus multiple dosing regimes of intravenous anti-staphylococcal antibiotics for methicillin-susceptible Staphylococcus aureus (MSSA): a systematic review. Antibiotics. 2020;9 https://doi.org/10.3390/antibiotics9020039.

  36. McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus. Yale J Biol Med. 2017; https://doi.org/10.1201/9780849340574-15.

  37. Walters MS, Eggers P, Albrecht V, Travis T, Lonsway D, Hovan G, Taylor D, Rasheed K, Limbago B, Kallen A. Vancomycin-resistant Staphylococcus aureus—Delaware, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1056. https://doi.org/10.15585/mmwr.mm6437a6.

    Article  PubMed  Google Scholar 

  38. Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. Int J Antimicrob Agents. 2011;37:219. https://doi.org/10.1016/j.ijantimicag.2010.10.029.

    Article  CAS  PubMed  Google Scholar 

  39. Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010;23:99. https://doi.org/10.1128/CMR.00042-09.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Roch M, Clair P, Renzoni A, Reverdy ME, Dauwalder O, Bes M, Martra A, Freydière AM, Laurent F, Reix P, Dumitrescu O, Vandenesch F. Exposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2014;58:5306. https://doi.org/10.1128/AAC.02574-14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52:3315. https://doi.org/10.1128/AAC.00113-08.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Chong YP, Park KH, Kim ES, Kim MN, Kim SH, Lee SO, Choi SH, Jeong JY, Woo JH, Kim YS. Clinical and microbiologic analysis of the risk factors for mortality in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2015;59:3541. https://doi.org/10.1128/AAC.04765-14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Burnham JP, Burnham CAD, Warren DK, Kollef MH. Impact of time to appropriate therapy on mortality in patients with vancomycin-intermediate Staphylococcus aureus infection. Antimicrob Agents Chemother. 2016;60:5546. https://doi.org/10.1128/AAC.00925-16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Saravolatz LD, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis. 2012;55:582. https://doi.org/10.1093/cid/cis492.

    Article  CAS  PubMed  Google Scholar 

  45. Prakash V, Lewis JS, Jorgensen JH. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother. 2008;52:4528. https://doi.org/10.1128/AAC.00904-08.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Swenson JM, Anderson KF, Lonsway DR, Thompson A, McAllister SK, Limbago BM, Carey RB, Tenover FC, Patel JB. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. J Clin Microbiol. 2009;47:2013. https://doi.org/10.1128/JCM.00221-09.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Jernigan JA, Farr BM. Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis. Ann Intern Med. 1993;119:304. https://doi.org/10.7326/0003-4819-119-4-199308150-00010.

    Article  CAS  PubMed  Google Scholar 

  48. Chong YP, Moon SM, Bang KM, Park HJ, Park SY, Kim MN, Park KH, Kim SH, Lee SO, Choi SH, Jeong JY, Woo JH, Kim YS. Treatment duration for uncomplicated staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study. Antimicrob Agents Chemother. 2013;57:1150. https://doi.org/10.1128/AAC.01021-12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Kleinschmidt S, Huygens F, Faoagali J, Rathnayake IU, Hafner LM. Staphylococcus epidermidis as a cause of bacteremia. Future Microbiol. 2015;10:1859. https://doi.org/10.2217/fmb.15.98.

    Article  CAS  PubMed  Google Scholar 

  50. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, Grady NPO, Raad II, Rijnders BJA, Sherertz RJ, Warren DK (2009) IDSA guidelines for IV catheters. Cid.

    Google Scholar 

  51. Argemi X, Hansmann Y, Riegel P, Prévost G. Is staphylococcus lugdunensis significant in clinical samples? J Clin Microbiol. 2017;55:3167. https://doi.org/10.1128/JCM.00846-17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Zinkernagel AS, Zinkernagel MS, Elzi MV, Genoni M, Gubler J, Zbinden R, Mueller NJ. Significance of staphylococcus lugdunensis bacteremia: report of 28 cases and review of the literature. Infection. 2008;36:314. https://doi.org/10.1007/s15010-008-7287-9.

    Article  CAS  PubMed  Google Scholar 

  53. Holland TL, Raad I, Boucher HW, Anderson DJ, Cosgrove SE, Suzanne Aycock P, Baddley JW, Chaftari AM, Chow SC, Chu VH, Carugati M, Cook P, Ralph Corey G, Crowley AL, Daly J, Gu J, Hachem R, Horton J, Jenkins TC, Levine D, Miro JM, Pericas JM, Riska P, Rubin Z, Rupp ME, Schrank J, Sims M, Wray D, Zervos M, Fowler VG. Effect of algorithm-based therapy vs usual care on clinical success and serious adverse events in patients with staphylococcal bacteremia a randomized clinical trial. JAMA. 2018;320:1249. https://doi.org/10.1001/jama.2018.13155.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Heldman AW, Hartert TV, Ray SC, Daoud EG, Kowalski TE, Pompili VJ, Sisson SD, Tidmore WC, Vom Eigen KA, Goodman SN, Lietman PS, Petty BG, Flexner C. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med. 1996;101:68. https://doi.org/10.1016/S0002-9343(96)00070-8.

    Article  CAS  PubMed  Google Scholar 

  55. Schrenzel J, Harbarth S, Schockmel G, Genné D, Bregenzer T, Flueckiger U, Petignat C, Jacobs F, Francioli P, Zimmerli W, Lew DP. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. Clin Infect Dis. 2004;39:1285. https://doi.org/10.1086/424506.

    Article  CAS  PubMed  Google Scholar 

  56. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother. 2005;56:923. https://doi.org/10.1093/jac/dki355.

    Article  CAS  PubMed  Google Scholar 

  57. Paul M, Bishara J, Yahav D, Goldberg E, Neuberger A, Ghanem-Zoubi N, Dickstein Y, Nseir W, Dan M, Leibovici L. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ. 2015;350:h2219. https://doi.org/10.1136/bmj.h2219.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, Bruun NE, Høfsten DE, Fursted K, Christensen JJ, Schultz M, Klein CF, Fosbøll EL, Rosenvinge F, Schønheyder HC, Køber L, Torp-Pedersen C, Helweg-Larsen J, Tønder N, Moser C, Bundgaard H. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380:415. https://doi.org/10.1056/nejmoa1808312.

    Article  CAS  PubMed  Google Scholar 

  59. Fowler VG, Li J, Corey GR, Boley J, Marr KA, Gopal AK, Kong LK, Gottlieb G, Donovan CL, Sexton DJ, Ryan T. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol. 1997;30:1072. https://doi.org/10.1016/S0735-1097(97)00250-7.

    Article  PubMed  Google Scholar 

  60. Côté G, Denault A. Transesophageal echocardiography-related complications. Can J Anesth. 2008;55:622. https://doi.org/10.1007/BF03021437.

    Article  PubMed  Google Scholar 

  61. Holland TL, Arnold C, Fowler VG. Clinical management of staphylococcus aureus bacteremia: a review. JAMA. 2014;312:1330. https://doi.org/10.1001/jama.2014.9743.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Tubiana S, Duval X, Alla F, Selton-Suty C, Tattevin P, Delahaye F, Piroth L, Chirouze C, Lavigne JP, Erpelding ML, Hoen B, Vandenesch F, Iung B, Le Moing V. The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with Staphylococcus aureus bacteremia. J Infect. 2016;72:544. https://doi.org/10.1016/j.jinf.2016.02.003.

    Article  PubMed  Google Scholar 

  63. van der Vaart TW, Prins JM, Soetekouw R, van Twillert G, Veenstra J, Herpers BL, Rozemeijer W, Jansen RR, Bonten MJM, van der Meer JTM. Prediction rules for ruling out endocarditis in patients with Staphylococcus aureus bacteremia. Clin Infect Dis. 2021;74:1442. https://doi.org/10.1093/cid/ciab632.

    Article  PubMed Central  Google Scholar 

  64. George MP, Esquer Garrigos Z, Vijayvargiya P, Anavekar NS, Luis SA, Wilson WR, Baddour LM, Sohail MR. Discriminative ability and reliability of transesophageal echocardiography in characterizing cases of cardiac device lead vegetations versus noninfectious Echodensities. Clin Infect Dis. 2021;72:1938. https://doi.org/10.1093/cid/ciaa472.

    Article  CAS  PubMed  Google Scholar 

  65. Bayer AS, Chambers HF. Prosthetic valve endocarditis diagnosis and management—new paradigm shift narratives. Clin Infect Dis. 2021;72:1687. https://doi.org/10.1093/cid/ciab036.

    Article  CAS  PubMed  Google Scholar 

  66. Choi SH, Dagher M, Ruffin F, Park LP, Sharma-Kuinkel BK, Souli M, Morse AM, Eichenberger EM, Hale L, Kohler C, Warren B, Hansen B, Medie FM, Mcintyre LM, Fowler VG. Risk factors for recurrent Staphylococcus aureus bacteremia. Clin Infect Dis. 2021;72:1891. https://doi.org/10.1093/cid/ciaa801.

    Article  CAS  PubMed  Google Scholar 

  67. Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, Basuino L, Mai TT, Marbach H, Braughton KR, Whitney AR, Gardner DJ, Fan X, Tseng CW, Liu GY, Badiou C, Etienne J, Lina G, Matthay MA, Deleo FR, Chambers HF. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci U S A. 2010;107:5587. https://doi.org/10.1073/pnas.0912403107.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Bae JS, Da F, Liu R, He L, Lv H, Fisher EL, Rajagopalan G, Li M, Cheung GYC, Otto M. Contribution of Staphylococcal enterotoxin B to Staphylococcus aureus systemic infection. J Infect Dis. 2021;223:1766. https://doi.org/10.1093/infdis/jiaa584.

    Article  CAS  PubMed  Google Scholar 

  69. Mohammad M, Hu Z, Ali A, Kopparapu PK, Na M, Jarneborn A, Stroparo M d N, Nguyen MT, Karlsson A, Götz F, Pullerits R, Jin T. The role of Staphylococcus aureus lipoproteins in hematogenous septic arthritis. Sci Rep. 2020;10:7936. https://doi.org/10.1038/s41598-020-64879-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Montgomery CP, Daniels MD, Zhao F, Spellberg B, Chong AS, Daum RS. Local inflammation exacerbates the severity of Staphylococcus aureus skin infection. PLoS One. 2013;8:e69508. https://doi.org/10.1371/journal.pone.0069508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Mölkänen T, Ruotsalainen E, Rintala EM, Järvinen A. Predictive value of C-reactive protein (CRP) in identifying fatal outcome and deep infections in staphylococcus aureus bacteremia. PLoS One. 2016;11:e0155644. https://doi.org/10.1371/journal.pone.0155644.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Corrales-Medina VF, Fatemi O, Serpa J, Valayam J, Bozkurt B, Madjid M, Musher DM. The association between Staphylococcus aureus bacteremia and acute myocardial infarction. Scand J Infect Dis. 2009;41:511. https://doi.org/10.1080/00365540902913460.

    Article  PubMed  Google Scholar 

  73. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007;45:158. https://doi.org/10.1086/518849.

    Article  PubMed  Google Scholar 

  74. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CCH, Newman A, Loehr L, Folsom AR, Elkind MS, Lyles MF, Kronmal RA, Yende S. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313:264. https://doi.org/10.1001/jama.2014.18229.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Blair A, Manian FA. Coexisting systemic infections in patients who present with a fall. Am J Med Sci. 2017;353:22. https://doi.org/10.1016/j.amjms.2016.11.010.

    Article  PubMed  Google Scholar 

  76. Smith MN, Brotherton AL, Lusardi K, Tan CA, Hammond DA. Systematic review of the clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening for MRSA pneumonia. Ann Pharmacother. 2019;53:627. https://doi.org/10.1177/1060028018823027.

    Article  PubMed  Google Scholar 

  77. Mergenhagen KA, Starr KE, Wattengel BA, Lesse AJ, Sumon Z, Sellick JA. Determining the utility of methicillin-resistant staphylococcus aureus nares screening in antimicrobial stewardship. Clin Infect Dis. 2020;71:1142. https://doi.org/10.1093/cid/ciz974.

    Article  CAS  PubMed  Google Scholar 

  78. Brüggemann H, Poehlein A, Brzuszkiewicz E, Scavenius C, Enghild JJ, Al-Zeer MA, Brinkmann V, Jensen A, Söderquist B. Staphylococcus saccharolyticus isolated from blood cultures and prosthetic joint infections exhibits excessive genome decay. Front Microbiol. 2019;10 https://doi.org/10.3389/fmicb.2019.00478.

  79. Wang P, Liu Y, Xu Y, Xu Z. Staphylococcus saccharolyticus infection: case series with a PRISMA-compliant systemic review. Medicine. 2020;99:e20686. https://doi.org/10.1097/MD.0000000000020686.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Al-Jebouri M. Antibiotics resistance among anaerobic pathogens causing human periodontitis. World J Pharm Pharm Sci. 2014;3:1720–33.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA

    Alexander M. Tatara

Authors
  1. Alexander M. Tatara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander M. Tatara .

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tatara, A.M. (2023). Staphylococcal Infection. In: The Infectious Diseases Consult Handbook. Springer, Cham. https://doi.org/10.1007/978-3-031-39474-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-39474-4_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-39473-7

  • Online ISBN: 978-3-031-39474-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation